Clinical Trial Update: Relative Bioavailability Study of Subcutaneous Injection Versus Intravenous Infusion of Pembrolizumab (MK-3475) in Participants With Advanced Melanoma (MK-3475-555/KEYNOTE-555) [Phase 1]

View source ↗

Summary

Phase 1 study comparing subcutaneous vs intravenous pembrolizumab in adults with advanced melanoma evaluated relative bioavailability; results have been posted …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Melanoma | Phase 1 | Status: COMPLETED | Results posted: 2025-02-10